Navigation Links
Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors
Date:7/15/2011

ANNAPOLIS, Md., July 15, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Board of Directors has elected Mitchel Sayare, Ph.D. to succeed John Pappajohn as Chairman of the Board. Mr. Pappajohn stepped down from the PharmAthene Board effective immediately.

Dr. Sayare has been a member of PharmAthene's Board of Directors since April 2010, and most recently served from 1985 until 2010 as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics.  During his long and successful tenure with ImmunoGen, Dr. Sayare was responsible for leading an IPO and raising over $400 million in venture capital and public equity financing for the company.  During this time, Dr. Sayare also served as President of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization.

Prior to joining ImmunoGen, Dr. Sayare served as Vice President, Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer.  In this role he oversaw all research and development, corporate development, and investor relations responsibilities for the company.  Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.

"Mitch has been an invaluable asset to our Company and we are delighted he has agreed to assume the Chairmanship of the Board of Directors," remarked Eric I. Richman, President and Chief Executive Officer.   "As a former Director and Treasurer of the Biotechnology Industry Organization (BIO), his extensive exper
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
2. Georgia Power to Delay Plant Mitchell Conversion to Biomass
3. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
6. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
7. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
8. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
9. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
10. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
11. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% of ... growth in China , as well as solid contributions from ... Europe / Middle East / ... gains in Germany , Turkey and ... / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... COLUMBIA, Md., Dec. 13 Martek Biosciences,Corporation announced ... DHA and,ARA license and supply agreement for infant ... Pharmaceutical. Under the terms of the,agreement, Martek will ... IlDong,Foodis infant formula products in South Korea., ...
... the US Oncology Adjuvant Trial 9735 at 2007 ... and Cyclophosphamide Improved Overall ... Dec. 13 Results presented at the,30th annual ... for,women with early stage breast cancer who have ...
... diseases for this collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic ... ... cancers in 2007 in ... US alone(1), -- MicroRNAs hold significant potential as highly sensitive and specific ...
Cached Biology Technology:Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 2Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 2Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 3Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 4Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 5
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Naturally occurring CD4+CD25+ Tregs are a specialized subpopulation of ... destroying self-tissues. But harnessing the therapeutic potential of Tregs ... diabetes and rheumatoid arthritis -- is hampered by problems ... because, unlike non-regulatory T cells, Tregs do not proliferate ...
... may originate from breast stem cells that have undergone ... from The Walter and Eliza Hall Institute, using mouse ... express receptors for the female hormones oestrogen or progesterone. ... aggressive 'basal' subtype of breast cancer. There is increasing ...
... has shown that the autistic brain has fewer neurons in ... a new study published in the July 19 issue of ... provides quantitative evidence linking autism to an abnormality of the ... to parts of the brain responsible for higher cognitive functions. ...
Cached Biology News:Breast stem cells have features similar to 'basal' tumors 2Autistic brain has fewer neurons for processing emotion 2
... BODIPY FL ATP-Gamma-S binds to ATP-binding ... the BODIPY FL fluorophore was linked ... addition to its potential use for ... thioether is an important new substrate ...
... Using information-rich MSn data, the patent-pending ... multiple levels of fragmentation, isotope pattern ... to accurately determine the correct formula ... approaches for deducing empirical formulae from ...
... peptide synthesis with a wide variety of purity ... research needs. Purity: IG(>50%), >70%, ... Sequence Length: Up to 120 ... C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA conjugation, and ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
Biology Products: